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The study of genetic epidemiology of cancers in Africa is unique as compared to first 
world countries, as it entails the combination of gene-environment interaction, poor 
socio-economic conditions and the high prevalence of infectious (e.g. tuberculosis and 
HIV) and non-infectious diseases.  Acute Promyelocytic Leukemia (APL), a subtype 
of Acute Myeloid leukemia (AML) if not diagnosed within 24 hours because of its 
hemorrhagic tendencies, becomes a medical emergency.  It has become one of the 
most treatment-responsive cancers due to its excellent response to all trans-retinoic 
acid (ATRA).  Advances in molecular diagnostics have resulted in a reverse- 
transcriptase polymerase chain reaction (RT-PCR) test to detect the PML-RARA 
(retinoic acid receptor alpha) transcript found in APL’s.  Globally, many centers have 
investigated the different breakpoint cluster regions (bcr) to classify the patients into 
different prognostic groups for specific molecular targeted treatment.  However, there 
are no reports from Africa on the frequency of the different isoforms in APL patients.  
In this study we aim to identify and determine the frequency of bcr isoforms in APL 
patients from a tertiary hospital in Kwa Zulu Natal (KZN) by quantitative RT-PCR 
(qPCR).  The correlation of the hematological parameters with the different isoforms 
was analyzed by descriptive non-parametric statistical analysis.  The qPCR confirmed 
bcr1 to be the predominant isoform (63,6%) followed by bcr3 (31,8%) and bcr2 
(4,5%).  There was a median age group of less than 45 in our patient cohort.  Patients 
with the bcr3 isoform had a poor prognosis according to their clinical risk 
stratification but this did not necessarily result in poor overall survival when 




different isoforms responded to “standard of care” treatment in the same way as non-


















































1.1  Introduction 
Leukemia represents a group of hematological malignancies characterized by clonal expansion of 
hematopoietic cells with uncontrolled proliferation, decreased apoptosis and blocked 
differentiation.  Among all malignancies, this group is ranked fifth for male and sixth for female 
mortality.  In addition, it is the leading cause of death in young people with cancer, with 300 000 
new cases and 222 000 deaths each year worldwide (Ahn Y O et al, 1991; Yang C & Zhang X, 
1991; Jemal A et al, 2005; Parkin D M et al, 2005). 
 
Due to the disease progression and hematopoietic lineages involved, (Bennet J M et al, 1985) 
leukemia can be divided into acute or chronic and lymphoid or myeloid types.  Subtypes are 
further classified based on the lineage and stage of differentiation.  Chromosomal abnormalities 
are the most important predictors of prognosis in AML.  The most common abnormality in APL 
with (t15;17)(q22;q12), a subtype of AML, is the PML-RARA (retinoic acid receptor alpha) 
fusion gene resulting from translocations, leading to fusion of the PML gene on chromosome 15 
in more than 90% of cases (Sazwal S et al, 2009).  In the case of a variant APL, RARA gene is 
replaced by five different partners with the PLZF being the most common (Mistry A R et al, 
2003; Campbell L J et al, 2013). 
 
Acute Promyelocytic Leukemia has evolved from one of the most fatal cancers to one that maybe 
curable.  Due to APL being a medical emergency because of its hemorrhagic tendencies, a rapid 
molecular diagnostic test such as PCR or fluorescent in situ hybridization (FISH) is essential, as 
other tests such as southern blotting or cytogenetics would take too long for the result to be 
obtained.  Molecular diagnosis of the bcr isoforms in APL and early assessment of treatment 
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response that use methodologies capable of detecting submicroscopic disease can determine 
subgroups of patients with leukemia at differing relapse risk (Lo–Coco F et al, 2010).   
 
Importantly, the responses of leukemia to therapies differ from one subtype to another, making 
individualized therapeutic strategies extremely useful.  Translational research across bedside to 
bench may not only shed light on leukemogenesis and gain insights into therapeutic mechanisms, 
but also provide opportunities for designing sophisticated individualized therapeutic protocols as 
highlighted by the development of curative approaches for APL (Gupta K et al, 2011).  
Monitoring for MRD during induction and consolidation by the detection of molecular targets 
offers personalized medicine with the ultimate goal of disease-free survival of the patient. 
 
Many studies have shown that detection of PML-RARA transcripts by qualitative nested RT-PCR 
predicts hematological relapse, whereas negative RT-PCR results are associated with long-term 
remission (Polampalli S et al, 2011; Coombs C C et al, 2015; Park J H et al, 2011).  The small 
number of reports that do not appear to follow this trend may reflect failure to collect specimens 
at critical time points, poor quality ribonucleic acid (RNA), and /or inherent differences in the 
sensitivities of the specific RT-PCR assays used (Lang L et al, 2007).  Therefore, accurate 
diagnosis is important for effective treatment.  Screening for known specific abnormalities by 
RT-PCR could lead to more definitive diagnosis (Nora-Athina Viniou et al, 1995; Sazwal S et al, 
2009). 
 
The interpretation of molecular assay results remains a contentious issue and highlights a need to 
define and standardize assays for detection of molecular relapse (van Dongen J J M et al, 2015).  
This is particularly important because clinical studies indicate that survival rates can be improved 
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by treating patients at molecular relapse (presence of PML-RARA transcripts) as opposed to frank 
hematological relapse (presence of abnormal promyelocytes and blasts on a differential count) 
(Slack J L et al, 2001; Sasaki K et al, 2015).  Studies suggest that sensitive, quantitative methods 
will improve the predictive power of molecular monitoring of APL compared to qualitative 
methods (Hussain I et al, 2011; Mandelli F et al, 1997; Polampalli S et al, 2011).   
 
The epidemiology and clinical outcome of AML in HIV-infected adults is poorly documented.  In 
a large study (16 AML cases) from 12 hematology centers in France, complete remission was 
obtained in 11 out of 15 HIV-infected patients; no deaths were related to AML treatment (Sutton 
L et al, 2001).  According to Statistics South Africa, the estimated overall HIV prevalence rate in 
South Africa is approximately 11.2%.  The total number of people living with HIV is estimated at 
approximately 6.19 million in 2015.  For adults aged 15-49 years, an estimated 16, 6% of the 
population is HIV positive (www.statssa.gov.za/publications/p0302).  
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1.2  Literature Review 
Acute Promyelocytic Leukemia is an (AML) subtype and represents less than 10% of all AML, 
an aggressive cancer of the bone marrow.  It was first characterized by Leif Hillestad in 1970 
(Stavem P, 1978); however cases resembling APL were reported from as early as 1935 (Risak, 
1935).  It was called APL because the white blood cell population was dominated by 
promyelocytes.  Hillestad (1990) and coworkers reported that patients with this form of AML had 
a 100% mortality rate, as there was a tendency for severe bleeding without effective treatment 
and concluded that APL was the most malignant form of acute leukemia. 
 
In 1976, the French-American-British (FAB) Nomenclature Committee assigned APL as the M3 
subtype of acute myeloid leukemia (AML: M3) as indicated in (Table 1.1), based on the unique 
morphology of promyelocytes in the bone marrow (Bennet J M et al, 1976).  In 2008, the World 
Health Organization (WHO) revised the FAB classification to include recurrent genetic 
abnormalities of AML.  Here, M3 was replaced with APL t (15; 17) (q22; q12) PML-RARA as 
depicted in (Table 1.2). 
 
Table 1.1:  FAB classification of AML  
FAB subtype Name Adult AML patients 
M0 








Acute myeloblastic leukemia with 
maturation 
25% 
M3 Acute promyelocytic leukemia 10% 
M4 Acute myelomonocytic leukemia 20% 
M4EOS 
Acute myelomonocytic leukemia with 
eosinophilia 
5% 
M5 Acute monocytic leukemia 10% 
M6 Acute erythroid leukemia 5% 
M7 Acute megakaryocytic leukemia 5% 
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Table 1.2:  WHO classification (2008) of AML and related neoplasm’s 
 
AML with recurrent genetic abnormalities 
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBEB-MYH11 
Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12); PML-RARA 
AML with t(9;11)(p22;q23); MLLT3-MLL 
AML with t(6;9)(p23;q34); DEK-NUP214 
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
Provisional entity: AML with mutated NPM1 
Provisional entity: AML with mutated CEBPA 
  
AML with myelodysplasia-related change 
  
Therapy-related myeloid neoplasms AML, not otherwise specified: 
Undifferentiated AML (M0) 
AML with minimal differentiation (M1) 
AML without maturation (M2) 
AML with maturation (M2) 
Acute myelomonocytic leukemia (M3) 
Acute monoblastic/monocytic leukemia (M4) 
Acute erythroid leukemia (M5) 
Pure erythroid leukemia (M6) 
Erythroleukemia, erythroid/myeloid (M6) 
Acute megakaryoblastic leukemia (M7) 
Acute basophilic leukemia 




Myeloid proliferations related to Down syndrome: 
  
Transient abnormal myelopoiesis 
Myeloid leukemia associated with Down syndrome 
  





1.2.1  Clinical and morphological features  
Acute Promyelocytic Leukemia is characterized by hyper granular morphology, severe 
coagulopathy, and an excellent clinical response to ATRA (Appelgate T L et al, 2002; Rego E M 
et al, 2015).  Bleeding in APL is due to acute disseminated intravascular coagulopathy (DIC) 
which occurs in 85% of patients when there is sudden exposure of blood to procoagulants (e.g. 
tissue factor or tissue thromboplastin) which generates intravascular coagulation (Park J H et al, 
2011).  It is characterized by rapid increase in the number of immature white blood cells, 
resulting in rapid increase of malignant cells and crowding of the bone marrow.  This results in 
very low red blood cell (anemia) and platelet counts, which exacerbate the bleeding diathesis in 
patients (Choudry A et al, 2012). 
 
Either leukopenia (low white cell count) or leukocytosis (high white cell count) may be observed 
in the peripheral blood.  Leukocytosis is only seen in about 25% of patients and organomegaly is 
rarely found on diagnosis (Chatterjee T et al, 2014).  Hemorrhagic findings such as gingival 
bleeding; ecchymoses; epistaxis or menorrhagia has also been observed in a few patients (Yusof 
M et al, 2010). 
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Figure 1.1:  APL (M3) scanned under 50 x oil objectives:  showing typical morphology from 
Patient X diagnosed with APL and admitted to the Hematology Ward (A4W) at Inkosi 
Albert Luthuli Central Hospital on the 22/02/2011.  
Abnormal promyelocytes are larger than their normal counterparts, with a nucleus that is bilobed, 
dumb-bell or kidney-shaped as depicted in (Figure 1.1).  It is morphologically distinguished by 
the presence of hyper-granular (M3) blasts as shown in (Figure 1.1) and bundles of auer rods or 
faggot cells as shown in (Figure 1.2) (Ludwig W D et al, 2012).  Anisocytosis, target cells and 
rouleaux formation of red blood cells may also be present.   
 9 
 
Figure 1.2:  APL M3 scanned under 50 x oil objectives: showing typical APL morphology 
with auer rods from Patient S diagnosed with APL and admitted to the Hematology Ward 
(A4W) at Inkosi Albert Luthuli Central Hospital on 31/07/2015. 
 
Figure 1.3:  AML M3v showing hypogranular promyelocytes; 50x (adapted from the 
American Society of Hematology Imagebank.org. The author John Lazarchick uploaded 
the slide on the 15/2/2004).   
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About 25% of APL diagnosed is microgranular or hypogranular (M3v) as shown in (Figure 1.3).  
At higher magnification of the cells, the nuclear convolutions are more apparent.  Azurophillic 
granules are present in the cell on the left (Figure 1.3).  In APL, myeloperoxidase (MPO) is 
strongly positive in all leukemic promyelocytes; this is especially helpful in microgranular APL 
which is sometimes confused with Acute Monocytic Myeloid Leukemia (AMML) (Arber D A et 
al, 2008). 
 
1.2.2  Role of RARA in granulopoeisis: 
In APL, there is an abnormal accumulation of immature granulocytes called promyelocytes 
(http://www.ucsfhealth.org/adult/medical_services/cancer/leukemia/conditions/aml/signs.html).  
Despite reports implicating the fusion proteins in leukemia, little is known about how their 
function relates to the normal function of the RARA during granulopoeisis, the process by which 
immature myeloid cells, such as promyelocytes, differentiate to mature neutrophils (Kastner P et 
al, 2000). 
 
The RARA gene is altered by chromosomal translocations in all cases of APL.  These 
translocations lead to the synthesis of chimeric proteins, resulting from the fusion of novel N-
terminal sequences to RARA amino acids (Melnick A et al, 1999).  Retinoic acid (RA) has been 
shown to act as a differentiating agent for both normal and transformed immature myeloid cells 
(Breitman T R et al, 1980).  At limiting RA concentrations, an increase in the proportion of 
unliganded RAR molecules may lead to a dominant-negative inhibition of RA-controlled 
differentiation.  Retinoic acid appears to orientate the differentiation of pluripotent hematopoietic 
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progenitors toward the granulocyte lineage, indicating that RA may be involved in granulocyte 
fate specification (Tocci A et al, 1996). 
 
1.2.3  The Normal and Mutated Function of PML and RARA  
The normal function of the RARA gene provides instructions for making a transcription factor.  A 
transcription factor is a protein that binds to specific regions of DNA and helps to control the 
activity of particular genes.  The RARA protein controls the transcription of genes important for 
differentiation of immature white blood cells (promyelocytes).  The RARA protein binds to 
specific regions of DNA and attracts other proteins that repress gene transcription, the first step to 
protein production.  In response to a specific signal, the repressive proteins are removed and other 
proteins that induce transcription and cell differentiation binds to the RARA protein. 
 
The PML gene provides instructions for a protein that acts as a tumor suppressor, which means it 
prevents cells from growing and dividing too rapidly in an uncontrolled way.  The PML protein is 
found in distinct structures in the nucleus of a cell called PML nuclear bodies.  Mutations can be 
acquired and present only in certain cells.  These mutations are called somatic mutations, and are 
not inherited.  A somatic mutation involving the RARA gene causes APL. 
 
The PML-RARA protein product from this fused gene functions differently from protein products 
of the normal PML and RARA genes.  The PML protein blocks cell growth, proliferation and 
induces apoptosis in combination with other proteins.  The PML-RARA blocks differentiation of 
blood cells at the promyelocyte stage and allows abnormal cell proliferation.  As a result excess 
promyelocytes accumulate in the bone marrow and normal white blood cells cannot form, leading 
to APL (https://ghr.nlm.nih.gov/). 
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1.2.4  RARA variants 
World Health Organisation designated a subset of AML’s morphologically similar to APL as 
shown in (Figure 1.5), but lacking both t (15; 17) by cytogenetics as shown in (Figure 1.4) 
and not detectable for PML-RARA by FISH (Arber D A et al, 2008).  In addition to the PML-
RARA rearrangement, four other APL associated translocation of the RARA gene have been 
characterized at the molecular level as shown in (Table 1.3).  As with other hematological 
malignancies partner genes affect both neoplastic phenotype and response to treatment 
including ATRA, making their identification crucial in the evaluation of these patients. 
 
At the molecular level, both PML-RARA and PLZF-RARA are strong repressors efficiently 
recruiting a complex containing the nuclear receptor corepressors N-COR/SMRT and histone 
deacetylase to target promoters.  These repressive properties are linked with their leukemogenic 
potential, as histone deacetylase inhibitors can reverse the leukemic phenotype and lead to 
remission in transgenic mouse models of APL similar to what was found in humans (He L Z et 
al, 1998). 
 
Since the PLZF gene was identified in an APL patient in 1993, a series of such cases have been 
reported.  The findings indicated that these patients were resistant to ATRA and had a generally 
poor response to chemotherapy (Licht J D et al, 1995).  In t(5;17) associated APL, RARA is 
translocated to a region on chromosome 5q35 containing the ubiquitous expressed and 
evolutionary conserved nucleophosmin (NPM) gene (Redner R L et al, 1996).  Nuclear Mitotic 
Apparatus is an abundant, conserved and ubiquitously expressed protein involved in the 
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completion of mitosis and re-formation of nuclei in the post-mitotic daughter cells (He D Z et al, 
1995).  The STAT5b-RARA fusion is the newest fusion partner with RARA, identified in a patient 
with AML with minimal differentiation (M1) but with a proportion of blasts exhibiting 
microgranular APL morphology (Arnould C et al, 1999).  Leukemic blasts from this patient 
failed to respond to ATRA in vitro.  
 
Table 1.3:  showing the RARA variants with their molecular and cytogenetic nomenclature 
Name of RARA variant Cytogenetic/Molecular 
Description 
Reference 
PML-RARA t(15;17)(q22;21) (Borrow J et al, 1990) 
Nucleophosmin(NPM-
RARA) 
t(5;17)(q35;q21) (Redner R L et al, 1996) 
Promyelocytic Leukemia 
Zinc finger (PLZF-RARA) 
t(11;17)(q23;21) (Chen Z et al, 1993)  
Nuclear Mitotic 
Apparatus(NuMA -RARA) 
t(11;17)(q13q21) (Wells R A et al, 1997) 




Figure 1.4:  RARA-PLZF t (11; 17) variant. Normal karyotypes for chromosomes 11 and 17 
are shown on the left. The translocation of 11 to 17 found in patients with the RARA-PLZF t 
(11; 17) variant is seen on the right.  Adapted from the Atlas Genetics and Cytogenetics 
Oncology, Haematology.1998; 2(3): 97-99, t (11; 17) (q23; q21) ZBTB16/RARA G- banding - 




Figure 1.5: Slide with typical RARA-PLZF morphology  with high rate of normal or 
dystrophic promyelocytes in peripheral blood and in bone marrow, no auer rods, 
myeloperoxidase reaction positive; immunocytochemical detection with an anti-PLZF 
shows a distinct punctuate nuclear distribution of the protein, suggesting its 
compartmentalization in the nucleus. 
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1.2.5  Molecular Pathogenesis of PML-RARA in APL 
The high frequency (70 to 100%) of the PML-RARA fusion gene in APL patients and the tumor 
type specificity of the t (15; 17) suggests that chromosomal break-points maybe crucial in the 
pathogenesis of this malignancy (Bassi S C et al, 2012).  Lo Coco (2006) and co-workers 
discussed that RARA fusion proteins may also interfere with cell survival, and this may contribute 
to their leukemogenic potential.  Expression of PML-RARA in hematopoietic cells inhibits 
programmed cell death; whereas in non-hematopoietic cells it induces apoptosis.  Progressive 
multi focal leukoencephalopathy possesses physiologic growth suppressor and pro-apoptotic 
properties that are disrupted by PML-RARA (Wang Z G et al, 1998).  Treatment with ATRA 
restores normal localization of PML, allowing the resumption of its physiologic functions. 
 
The molecular mechanisms by which PML-RARA deregulates PML intracellular pathways are not 
clear.  Progressive multi focal leukoencephalopathy localizes within distinct nuclear bodies 
(Dyck J A  et al, 1994).  The PML nuclear bodies are destroyed in APL cells and are restored 
after ATRA treatment, as a direct consequence of PML-RARA degradation (Nervi C et al, 1998).  
Also, PLZF is a growth suppressor that localizes within nuclear bodies (Ruthardt M et al, 1994).  
Thus, nuclear bodies could be involved in negative growth control and their deregulation by 
RARA-fusion proteins might represent a critical step during promyelocytic leukemogenesis.  
RARA chromosomal rearrangements represent the genetic hallmark of APL.  The tight association 
between RARA alterations and APL suggests that a normal RARA-dependent function must be 
altered to transform promyelocytes.  Fusion of RARA with PML or PLZF has been shown to be 
required to induce APL (Kogan S C, 2000). 
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Acute Promyelocytic Leukemia patients expressing a bcr3 isoform of PML-RARA appear to 
undergo additional cytogenetic changes compared with patients expressing the bcr1 isoform 
(Slack J L et al, 1997).  Using a murine APL model, Walter M J (2007) and coworkers also 
suggested that the bcr3 isoform of RARA/PML (RP3) may facilitate the acquisition of Del (2) in 
mice.  The study of this mechanism may provide valuable insight into the ways by which 
cytogenetic changes involving chromosomal copy number may occur in some patients with 
AML. 
 
Over the last few years, it has been established that the RARA variant genes(X) which results in 
the variant RARA fusion proteins (X-RARA), play a key role in the pathogenesis of APL through 
the recruitment of co-repressors and the histone deacetylase (HDAC)-complex, to repress genes 
implicated in myeloid differentiation (Mistry A R et al, 2003; Campbell L J, et al, 2013). 
 
1.2.6  PML-RARA Isoforms in APL 
Based on the genomic breakpoint in the PML gene, three different PML-RARA isoforms are 
recognized: bcr3 within intron 3 and bcr1 and 2 within intron 6 as shown in (Table 1.4) (Sazwal S 
et al, 2009).  The three respective mRNA types, short (S)-form, long (L) form and variable (V)-
form, can exhibit different phenotypes but do not affect complete remission (CR) rate or disease-
free survival (DFS).   
 
The chromosomal breakpoints in RARA are localized within a 15kb DNA fragment of the RARA 
intron 2 on chromosome 17.  In contrast, three regions of the PML locus on chromosome 15 are 
involved in the translocation breakpoints: intron 6 (bcr1; 55% of cases), exon 6 (bcr2; 5%) and 
intron 3 (bcr3; 40%) (van Dongen J J M et al, 1999).  Chimeric PML-RARA and RARA-PML 
 17 
transcripts are formed as a consequence of the reciprocal translocation between the PML and 
RARA loci.  The existence of different breakpoint regions in the PML locus and the presence of 
alternative splicing of PML transcripts are responsible for the great heterogeneity of PML-RARA 
transcript sizes observed among APL patients (Biondi A et al, 1992).  Moreover, the alternative 
usage of two polyadenylation sites generates additional PML-RARA transcripts of different sizes.  
The observation that RARA-PML transcripts are present in most but not all APL cases, has 
favored the use of PML-RARA transcripts as PCR targets for detection of APL cells at diagnosis 
and during monitoring (Grignani F et al, 1993; van Dongen J J M et al, 1999). 
 
Several studies attempted to correlate the type of PML-RARA transcript either with clinico-
biologic features at diagnosis or with treatment response and outcome (Sazwal S et al, 2009; 
Chatterjee T et al, 2014).  The vast majority of analyzed series compared the two major PML- 
RARA isoforms, (PML bcr1 and bcr2) and (PML bcr3) as summarized in (Table 1.4).  At 
diagnosis no correlations was found with respect to sex, platelet count, presence of coagulopathy 
or “differentiation syndrome”, when comparing patients with L-type or S-type PML-RARA 
transcripts.  However, patients with S-type transcripts had significantly higher white blood cell 
counts and more frequently display variant microgranular APL (M3v) morphology.  Although S-
type transcripts correlated with established adverse prognostic features at diagnosis (i.e. hyper- 
leukocytosis, M3v), compared to the L-type transcript, this association did not translate into poor 
treatment outcome such as relapse, in the context of combined ATRA and chemotherapy 






Table 1.4:  Differences in PML-RARA transcripts in APL Patients 
L/V-type  S- type  
PML bcr1 and 2 PML bcr3 
Intron 6 and exon 6 Intron 3 
Low and normal White Cell Count High White Cell Count (hyperleucocytosis) 
Good and intermediate prognosis Intermediate and poor prognosis 
 
1.2.7  Epidemiology of APL PML-RARA bcr isoforms 
In a study by Kudo K (1998) and coworkers the development of therapy related (t-AML) AML 
was investigated in 17 APL patients of mixed race mostly Italians and Japanese.  It was found 
that the development of t-APL is specific to genetic factors among different ethnic groups.  A 
study in the United States (US) showed the percentage of African–Americans with APL with t 
(15;17) (q22;q12) and abnormal cytogenetics was almost twice that of whites.  This could be due 
to more environmental exposures that predispose them to cancer and bone marrow stem cell 
disorders compared to whites http:file://E:\Differences in factors and outcomes in African 
Americans and whites with AML.mht.  The study of Sazwal S and coworkers, (2009) in India 
showed the presence of bcr3 (S-isoform) in Indian APL patients to be higher than the bcr1 (L- 
isoform).  Similarly, in the study of Hassan R (2014) and coworkers the S-form (35%) was 




1.2.8  Laboratory Diagnosis 
1.2.8.1  Routine Hematology tests 
Blood or bone marrows are sent for routine investigation such as full blood count, differential 
count, DIC, and cytochemical stains (Sudan Black, myeloperoxidase (MPO) and combined 
esterase). The cytochemistry can be omitted if four–colour flow cytometry is available (Milligan 
D.W et al, 2006).  A blood smear is scanned for auer rods or ‘faggot cells” and blasts under the 
microscope.  
  
1.2.8.2  Immunophenotyping 
Immunophenotyping by flow cytometry was recommended for the management of AML in 
adults.  It is available in most hematology diagnostic laboratories although different laboratories 
may use different acute panels of antibodies due to budget constraints.  CD3, CD7, CD13, CD14, 
CD33, CD34, CD64, CD117 and cytoplasmic MPO are quantified at diagnosis using flow 
cytometry (Milligan D.W et al, 2006). 
 
Acute Promyelocytic Leukemia cells are usually CD13 positive and CD33 positive, but are 
characterized by low or absent expression of HLA-DR, CD34, CD11a, CD11b, CD18 and CD117 
(Paietta E et al, 2004).  Hypogranular APL frequently co-expresses CD34 and CD2 (Exner M et 
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al, 2000).  Expression of CD56 has been observed in about 20% of cases and confers a worse 
outcome (Ferrara F et al, 2000). 
1.2.8.3  Specialized hematology tests 
All molecular tests are considered specialized test.  RT-PCR is used for the detection of the PML-
RARA fusion gene and is an important guide for treatment management.  The unique PML-RARA 
aberration serves as a marker for rapid diagnosis and prediction of response to ATRA and ATO 
therapies.  Low cost PML nuclear staining is extremely useful in countries with limited resources 
as a rapid genetic diagnosis.  Wild- type PML protein is localized in the nucleus of the cells, 
forming nuclear bodies (2-20 per nucleus that appear as speckled dots (Koken M H et al, 1994).  
With co-localization of PML and RARA in the nucleus, this changes the appearance to a 
microgranular pattern.  The micro granular pattern reverts to normal after treatment with ATRA 
(Daniel M T et al, 1993).  The PML pattern has proven useful for the diagnosis of PML-RARA 
positive APL.  
 
1.2.8.4  Cytogenetic and Molecular Diagnostic assays 
The combination of cytogenetic, FISH and molecular analysis provides a powerful approach for 
diagnosing and sub classifying malignant diseases into relevant clinical and biological subgroups.  
This is necessary in selecting appropriate therapy and in monitoring the efficacy of therapeutic 
regimens.  In cryptic and complex APL, the classic t (15; 17) is absent on routine cytogenetic 
assays.  However, the leukemia is morphologically and clinically similar to t (15; 17) positive 
APL and is treated as such (Grimwade D et al, 2000).  In these unusual cases, other methods are 
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needed for identification, such as FISH, RT-PCR and direct sequencing.  FISH uses a dual colour 
dual fusion probe to detect PML-RARA rearrangements.  The typical normal FISH pattern has 
two red signals (2R) and two green signals (2G) for the PML and RARA loci respectively.  When 
t (15; 17) is present, the characteristic FISH pattern has one red, one green and two fusion 
signals. 
 
However, it is possible to detect false-negatives using standard FISH probes on t (15; 17) APL 
cases with insertions, as FISH is often not sensitive enough to detect small cryptic insertions 
(Wang Y et al, 2009).  Therefore, RT-PCR should be used to confirm the detection of the PML-
RARA fusion gene.  
  
RT-PCR may also fail to identify poor quality samples (low copy number) and standardization 
has proven challenging (Grimwade D et al, 2014).  Another disadvantage of this method is that it 
lacks the capacity to quantify the levels of leukemia-specific transcripts.  Quantitative real-time 
PCR (qPCR) has definite advantages over RT-PCR as it enables absolute quantification of the 
leukemic target and endogenous control gene transcripts, which is useful in MRD monitoring and 
directed therapy.  The standardized PML-RARA qPCR assay has been shown to increase MRD 
detection rates compared to conventional, nested RT-PCR.  Although qPCR assays for the major 
leukemia-associated fusion transcripts have been standardized at the international level, there is 
still limited prospective data on the use of such assays to individualize therapy (Grimwade D et 







1.2.9  Treatment 
1.2.9.1  History of ATRA 
All trans- retenoic acid  (daily dose of 45mg/m
2
) was first used to treat patients at diagnosis in 
Shanghai (Huang M E et al, 1988).  After a collaborative meeting in Shanghai in 1987, the 
Chinese drug was kindly provided to treat patients in Paris, France (Castaigne S et al, 1990).  
Treatment of ATRA was proposed for newly diagnosed patients in Shanghai (Huang et al, 1988) 
and to treat relapsed patients in France.  Instead of the normal initial worsening with 
chemotherapy, coagulopathy rapidly improved.  The most remarkable features were the 
progressive change of malignant cells in the bone marrow (Castaigne S et al, 1990).  
 
In relapsed APL, ATRA, idarubicin and ATO recommended by the National Comprehensive 
Cancer Network (NCCN) can induce complete morphological, cytogenetic and molecular 
remission (Coombs C C et al, 2015).  Laboratory and clinical research studies have contributed to 
transform this once rapidly fatal disease into the most successful examples of translational 
research in medicine (Lo Coco F et al, 1999).  Within the first 10 days of treatment, 5-10% of 
APL patients will develop fatal hemorrhage, especially in the CNS and lungs (Rodeghiero F et al, 
1990).  ATO and ATRA have both been shown to quickly correct this coagulation disorder, and 
the initiation of the latter has become a true emergency in any new APL patient.  ATRA should 
be promptly started when APL is clinically and cytologically suspected even if cytogenetic and 
molecular confirmations of the diagnosis are pending (Sanz M A et al, 2009). 
 
 23 
1.2.9.2 Mechanisms of ATRA 
Phenotypically, pharmacological doses of ATRA lead to effective differentiation of immature 
APL cells to terminally differentiated granulocytes.  The binding of ATRA to RAR receptors 
causes degradation of PML-RARA protein through the ubiquitin–proteasome and caspase system, 
leading to restoration of terminal differentiation of promyelocytes.  Exposure of APL cells to 
ATRA in vitro or in vivo induces relocalization of PML and restores the normal structure.  Under 
the action of ATRA, co repressor (CoR) is dissociated from the repressive complex, whereas the 
co activator (CoA) is recruited to the complex.  As a result, the repression of transcriptional 
activation of target genes is relieved and the differentiation of promyelocytes is restored (Zhi-
Xiang Shen, 2009). In vitro cell culture has shown that ATRA-induced differentiation also 
coincides with activation of apoptosis (Grignani et al, 1998).  Although ATRA appears to be 
highly effective in clearing the bulk of proliferative tumor cells, a residual population of cells 
with detectable t (15; 17) almost invariably persists following treatment with this reagent alone; 
therefore additional chemotherapy, such as ATO is needed to achieve complete remission (Chen 
G et al, 1991).   
 
1.2.9.3  Mechanism of ATO-based APL therapy 
Compared to ATRA, ATO is less able to induce terminal differentiation of APL cells.  In vitro 
studies using cultured cells have revealed a dose-dependent effect of this drug on differentiation 
and apoptosis (Chen G et al, 1997).  At high concentrations (0.5-2.0 uM) ATO induced cell death 
by apoptosis, while at low concentrations (0.1-0.25 uM) this drug caused partial differentiation of 
APL cells along the granulocyte lineage (Cai X et al, 2000).  Arsenic trioxide -mediated 
differentiation has been shown to become dramatically enhanced in the presence of cyclic 
adenosine monophosphate (cAMP).  The mechanism responsible for this synergistic effect was 
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proposed to be the combined effect of ATO-induced PML-RARA degradation and cAMP-
mediated inhibition of cell cycle progression (Zhu J et al, 2002). 
 
At the molecular level, ATO exerts its therapeutic effect on APL in part by initiating a cascade of 
biochemical alterations that primarily affect the PML moiety of PML-RARA.  In addition to 
affecting differentiation of leukemic cells, recent studies have also implicated ATO in clearance 
of leukemic-initiating cells (LICs), a small population of malignantly transformed cells with stem 
cell characteristics that are frequently refractory to cancer therapeutic drugs.  PML-RARA 
expression has been reported to support properties of self-renewal of LICs (Wojiski S et al, 2009) 
ATO also increases radioactive oxygen species (ROS) production in malignant cells.  As a 
consequence, this drug leads to disruption of the mitochondrial membrane potential, followed by 
cytochrome C release, capase activation and subsequent apoptotic cell death (Jing Y et al, 1999).   
 
1.2.9.4  Current treatment 
It is now apparent that the nature of the RARA- fusion partner is a critical determinant of response 
to ATRA and arsenic, underlining the importance of cytogenetic and molecular characterization 
of patients with suspected APL to determine the most appropriate treatment approach.  Combined 
treatment with ATRA and anthracycline-based chemotherapy is highly successful in APL, 
providing longer remissions and probable cures in up to 70% newly diagnosed patients (Tallman 
M S et al, 2002).  The persistence of resistant clones causing relapse and low survival still 
represents a problem in 15-25% of patients and can be identified by MRD monitoring (Mistry A 




1.2.9.5  Future treatment 
The challenge for future studies is to improve complete remission through reduction in induction 
deaths, identifying patients to stratify in different risk groups, thereby reducing the risks of 
treatment toxicity and development of secondary leukemia or myelodysplasia.  With the advent 
of ATRA and arsenic, APL has already provided the first example of successful molecular 
targeted therapy and with further understanding of the pathogenesis of the disease, the next 
decade will find further improvements in the treatment of these patients (Mistry A R et al, 2003). 
 
1.2.10  Minimal Residual Disease (MRD) 
The study by Carlos S, (2007) and coworkers confirmed the need for MRD analysis by frequent 
sampling (at least every 4 months) in patients who have a molecular result with >10 normalized 
copy number (NCN) or reconfirmed positivity by RT-PCR.  Studies of APL over the last decade 
have resolved some issues to predict clinical outcome but there are important issues to be 
clarified.  Four treatment regimens have been instrumental in treatment of MRD in 2005.  First, 
Fenaux P et al, (2009) found that concurrent treatment with ATRA and chemotherapy (CT) 
resulted in superior long-term outcome.  Second, Lo-Coco F, (1999) and coworkers provided 
evidence that re-treatment at the time of molecular relapse during first remission provided 
improved clinical outcome.  Third, Sanz M A, (2009) and coworkers defined pre-treatment 
criteria to classify patients for risk of disease recurrence following concurrent ATRA-CT and 
introduced risk-adapted consolidation therapy with dose intensification and ATRA 
supplementation for intermediate patients.  Fourth, the availability of alternative agents, 
particularly ATO, has led to the formulation of novel induction regimens, which may add to the 
effectiveness of ATRA- AraC chemotherapy (ATRA-CT) or which may reduce or avoid the 
potential adverse effects of chemotherapy (Burnett A K et al, 1998).  Papanikolaou NA, (2010) 
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and coworkers proposed that targeting APL with ATRA combined with small molecule inhibitors 
of cyclin-dependant kinases maybe more effective than current regimens affording reduced 
toxicity and relapse rates. 
 
Detection of PML-RARA transcripts by molecular techniques constitutes an important tool for 
monitoring MRD and predicting evolution in APL patients especially at consolidation and 
maintenance (Sanz M A et al, 2005).  Conventional qualitative RT-PCR has been widely used for 
genetic diagnosis and therapeutic monitoring of APL.  Several reports have shown that RT-PCR 
positivity after consolidation therapy predicts hematology relapse, whereas persistent RT-PCR 
negativity is associated with long term survival and a low relapse rate (Jurcic J G et al, 2001; 
Mandelli F et al, 1997).  However, RT-PCR have several disadvantages such as the occurrence of 
false positives due to cross-contamination, false negatives due to poor RNA quality or PCR 
inhibition, low sensitivity for measuring MRD, time and labor-consuming and inter-laboratory 
variability.  Recently qPCR has become a new alternative for MRD.  It has several advantages 
such as being highly sensitive and reproducible. 
 
In a study by (Grimwade D et al, 2009) qPCR was used to monitor a large cohort of newly 
diagnosed patients with APL who were treated with standard ATRA and anthracyline-based 
chemotherapy to direct pre-emptive therapy with ATO and to guide transplantation in those who 
experienced failure with first-line therapy.  It was found that a log reduction in leukemic 
transcripts after induction did not predict relapse risk. 
 
This study shows that sequential MRD monitoring provides an alternate strategy that allows 
additional therapy to be targeted to patients at risk for relapse which is also cost-effective.  Due to 
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concerns that patients are currently over treated, there has been an increasing trend, with the 
availability of molecular targeted therapy towards de-intensification of APL therapy, with interest 
in chemotherapy-free schedules based on ATRA and ATO (Estey E H et al, 1999). 
 
It was found by Carlos S (2007) and coworkers that no significant differences in PML-RARA 
NCN values post-induction were obtained between relapsed patients and those who remained in 
continuous complete remission.  Also, the kinetics in tumor burden did not correlate with disease 
outcome.  These results contrast with the findings in other leukemic disorders such as t (9; 22) 
and t (8; 21) in which successful induction therapy produces a 2 to 3 log reduction in the level of 
transcripts.  The low number of positive cases detected at the end of consolidation limits the 
utility of qPCR to monitor MRD in APL patients. 
 
1.2.11  Risk Stratification 
Presently most centers use the Europe against Cancer (EAC) protocol (Gabert J et al, 2003) as 
explained in the methods section for risk stratification.  Risk stratification is imperative in the 
treatment of APL patients, as those with low-risk disease (WBC <10000/ul) have a less intensive 
treatment regimen (Grimwade D et al, 2009).  APL has evolved from the ATRA + chemotherapy 
backbone for all patients to ATRA and ATO and no chemotherapy in low-risk patients as a new 
standard of care.  Given the favorable results from risk-adapted treatment strategies, first in the 
LPA99 trial followed by the LPA2005 trial, the National Comprehensive Cancer Network 
(NCCN) recommended an alternate approach in induction which includes ATRA plus idarubicin 
and ATO (Coombs C C et al, 2015). 
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It was found that ten percent of all APL cases lack the classic t (15; 17).  This group includes 
cases with PML-RARA gene rearrangements like the t (5; 17) which are retinoid responsive and 
the t (11; 17) (q23; q21) that are retinoid-resistant.  It is imperative to treatment to distinguish 
subtypes of APL.  A European workshop was held in Monza, Italy in (1997) to develop a novel 
morphological classification system that takes into account the major nuclear and cytoplasmic 
features of APL (Danielle, S et al, 2000). 
 
Several genetic and phenotypic characteristics of APL blasts provide relevant targets and the 
rationale for tailored treatment.  Agents currently used are retinoids, ATO, anthracyclines and 
anti-CD33 monoclonal antibodies which have been taken off the market due to toxicity.  Novel 
agents that maybe used in the future are histone deacetylase and FLT3 inhibitors (Lo Coco F et 
al, 1999).  
 
1.2.12  Cure rates of APL 
Acute Promyelocytic Leukemia is the AML with the best prognosis.  Currently around 90% of 
newly diagnosed patients with APL achieve complete remission and over 75% are curable 
(Degos L et al, 2003).  Unfortunately the treatment outcome for patients in developing countries 
with APL is significantly inferior compared with that reported in Europe and United States (US).  
The International Consortium on APL (IC-APL) was established to create a network of 
institutions in developing countries to receive support from well-established US and European 
cooperative groups.  This resulted in a decrease of almost 50% in early mortality and an 
improvement in OS of almost 30% compared with historical controls, resulting in OS and DFS 
similar to those reported in developed countries (Rego E M et al, 2013). 
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To further increase the CR and cure rates detection and diagnosis of this disease at its early stage 
is very important (Ohno R et al, 2003).  A study by Park J H, (2011) and coworkers confirmed 
that the early death rate remains high despite the increased awareness of the disease and 
improved diagnostic tests and ATRA.  APL needs to be recognized by all clinicians as a medical 
emergency and major improvements in the early death and cure rates of APL will not only 
depend on new drugs but on the education of health care providers across a wide range of 
medical fields.  
 
1.2.13  HIV and AML 
HIV-1 infected individuals have a markedly increased incidence of cancers, such as Karposi’s 
sarcoma and non-Hodgkin lymphoma, however the risk of AML is at most slightly increased 
(Sutton L et al, 2001).  The study by Sutton L (2001) and coworkers surveyed all Hematology 
centers from 1990 to 1996 for AML patients at diagnosis that were HIV sero-positive.  This study 
showed a two-fold increase in the risk of AML in HIV-infected patients compared with the 
general population in France, although a larger cohort of patients need to be studied to confirm 
this.  They found that HIV-1-associated opportunistic infections did not occur during 
chemotherapy of AML induced aplasia.  CR and long- term leukemia- free survival were 
associated with a CD4
+
 cell count above 200 x 10
6
/l at AML diagnosis.  On the other hand, 
known long term HIV infection or full blown AIDS at AML diagnosis were associated with poor 





It was reported by Allers K (2010) and co-workers that an HIV positive patient with AML was 
“cured” of HIV infection after a stem cell transplant combined with high dose chemo and 
radiation therapy.  The stem cell donor had an extremely rare gene mutation (CCR5 gene 
spanning the 32-region from nucleotide 826 to 1138 on chromosome 3p21.31 (accession no: 
NM_000579) which protected him from HIV infection.  Although ARV therapy to suppress HIV 
had been stopped, the patient had shown no signs of HIV for over 36 months since the transplant 
occurred.  However the patient did relapse with AML but remains free from HIV. 
 
1.2.13.1  APL in HIV-infected Patients 
While the incidence of AML in HIV-infected patients has increased approximately twofold, the 
occurrence of APL is still exceedingly rare compared with the general population.  Due to the 
very small number of reported HIV positive APL patients who have been treated with different 
therapies, as well as the variable outcome, the prognosis of APL in the setting of the HIV-
infection is unclear.  Due to considerable risk for relapse, standard treatment of APL together 
with HAART should be used in HIV infected patients (Boban A et al, 2009).  Therapeutic 
strategies should target both pathologies, as ATRA has been found to induce apoptosis in HIV-
infected leukemic cells and protease inhibitor therapy has been reported to be synergistic with 
ATRA in inducing differentiation of APL cell lines (Drilon AD et al, 2010).   
 
The purpose of this descriptive study was to follow up patients for two years to detect MRD with 
qPCR.  Due to APL’s excellent response to molecular targeted therapy (ATRA) the occurrence of 
different isoforms and their effect on treatment response in APL, were also analyzed.  We also 
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aim to correlate the hematological parameters, clinical features and prognostic groups to the bcr 
isoforms.   
 
1.3  Rationale 
 To our knowledge there are no reported findings among South African patients, with 
limited data on the frequency of APL patients, the distribution of bcr isoforms and their 
treatment outcome in Africa as a whole.  
 In 2005, there were many reports showing that bcr3 patients had a poor prognosis than 
bcr1 or bcr2 patients; therefore it was important to use an assay that could identify the 
different bcr region to diagnose APL patients for treatment. 
 
1.4  Aims and Objectives 
Aim 
To determine the distribution of PML-RARA isoforms in APL patients from a tertiary hospital in 
KZN, South Africa (S.A). 
 
Objectives 
1  To determine the occurrence of APL in a referral hospital in KZN, (S.A) from samples 
collected in 2007. 
2  To identify PML-RARA bcr isoforms for the detection of the t (15; 17) translocation using a 
commercial kit. 
3  To correlate the hematological parameters with the different PML-RARA isoforms. 



























2.1  Clinical Risk Stratification Protocol (IALCH) (Grimwade D et al, 2009) 
On presentation patients were assigned to prognostic groups according to these hematological 
parameters:  
1. Good prognosis: WBC (white blood cells) <10 and platelet count >40 
2. Intermediate prognosis: WBC<10 and platelet count <40 
3. Poor prognosis: WBC>10 
 
2.2  Patient cohort  
 
From 2007 to 2009, ninety one patients attending the Onco-Hematology outpatient’s clinic at 
Inkosi Albert Luthuli Hospital (IALCH) with clinical signs and symptoms of Acute Leukemia 
were screened for this study.  Twenty two sequential adult APL patients (over the age of 18 
years) were chosen to be part of this study.  There were nine pediatric APL patients excluded 
from the study.  The study was conducted in accordance with the UKZN Biomedical Research 
Ethics guidelines (Ref no: BF070/07). 
 
Residual peripheral blood and/or bone marrow samples that were sent for routine laboratory 
analysis at diagnosis were used for molecular analysis.  The routine laboratory analysis included 
full blood count, platelet count, HIV testing, CD 4 count, international normalized ratio (INR), 
activated partial thromboplastin time (aPTT), fibrinogen, protamine sulphate and fibrinogen 
degradation product (D-Dimers).  Clinical diagnosis as well as preliminary laboratory tests such 
as the differential stain was used to diagnose the acute promyelocytic leukemia (APL-M3) 
according to WHO classification. 
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Immunophenotyping using single colour flow cytometry was performed to further subtype AML 
in another section of the laboratory.  Florescent in situ hybridization and cytogenetic analysis 
were conducted in an external referral laboratory according to the International System for 
Human Cytogenetic Nomenclature (ISCN; 2005) on one patient to confirm the variant APL.  A 
comprehensive dataset of the qPCR results in (Table 3.1) of each patient was recorded.  
Peripheral blood from five healthy donors as shown in (Table 3.3) was taken to serve as negative 
controls.   
 
2.3  MRD Protocol for samples 
Bone marrow aspirates and trephines were taken routinely at diagnosis.  Bone marrow was also 
taken post induction of chemotherapy and after the three courses of consolidation.  While on a 
maintenance program bone marrow trephines were performed six monthly.  A bone marrow 
trephine was also done on completion of maintenance.  In some cases, where the patient had 
adverse side-effects, blood was collected instead of bone marrow. 
 
2.4  IALCH Standard Treatment Protocol for Clinical Management of APL-Front Line 
Therapy 
 
For induction the following treatment was given: 
ATRA 45mg/m
2 
po (orally) plus Daunorubicin 70 mg/m
2 
ivi x 3/7 (for 3 days) regardless of 
WBC. ATRA was given to the patient throughout induction.  ATRA was continued until 
morphological remission (the patient cannot be diagnosed for APL by differential count).  For 
consolidation three cycles of anthracycline was given based on the patient’s response to therapy.  
For patients with a good prognosis the treatment was as follows:  
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1.  Idarubicin 5 mg/m
2  
x ivi 4/7 (for 4 days) + ATRA 45mg/m
2   
daily po x 2/52 (twice a 
year) 
2.  Mitoxantrone 10 mg/m
2  
x ivi 5/7 (for 5 days) + ATRA 45mg/m
2   
daily po x 2/52  
3.  Idarubicin 12 mg/m
2  
x ivi 1/7 (for 1 day) + ATRA 45mg/m
2   
daily po x 2/52 
 
For patients with an intermediate or poor prognosis the treatment was as follows: 
1.  Idarubicin 7 mg/m
2 
x ivi 4/7 + ATRA 45mg/m
2   
daily po x 2/52 
            2.  Mitoxantrone 10 mg/m
2 
x ivi 5/7 + ATRA 45mg/m
2   
daily po x 2/52  
3.  Idarubicin 12 mg/m
2 
x ivi 2/7 + ATRA 45mg/m
2   
daily po x 2/52 
Maintenance therapy was carried out monthly for 24 months: 6-Mercaptopurine 100 
mg/m
2 
po daily; Methotrexate 10 mg/m
2 
po weekly; ATRA 45 mg/m
2 
po x 2/52 every 
three months (Dr S. Parsanath; Clin Haem; IALCH). 
 
2.5  Erythrocyte Lysis and Trizol Treatment 
A table for all reagents used is provided in the (Appendix 6.4).  Samples were received at the 
laboratory within four hours of collection.  The blood or bone marrow was immediately lysed and 
the RNA was extracted as described below.   
 
Five volumes of EL Buffer (Qiagen; SA) was added to one volume of peripheral blood or bone 
marrow aspirate in the biosafety cabinet (LABAIRE, Microbiological Safety Cabinet, Class II) 
and placed on ice for 15 minutes.  After vortexing (Heidolph, Reax Top, Germany, 230V, 50Hz), 
the tubes were centrifuged (Jouan BR4i, France, 3000rpm) for 10 minutes at 4
o
C.  The resulting 
supernatant was decanted and discarded.  Two volume of cold EL Buffer was added to the white 
cell pellet.  The contents were vortexed and centrifuged again for 10 minutes at 4
o
C.  The 
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supernatant was decanted and the pellet retained.  Trizol reagent was added to the pellet and 
vortexed.  The pellet was then disrupted and homogenized using an 18 gauge needle and syringe.  
Trizol reagent was added 10x the size of the pellet until a homogenous solution with reduced 
viscosity was achieved.  The trizol pellets were then stored in 1ml aliquots in the -20
 o
C freezer.  
 
2.6  RNA Isolation 
Ribonucleic acid was isolated as per manufacturer’s instructions, (Lifetech, S.A).  Briefly; the 
centrifuge was cooled for 15 minutes at 2-8 ºC.  The homogenates were thawed at room 
temperature and placed in a 37 ºC heating block (Biometra, TB1, Germany) for 5 minutes to 
permit the complete dissociation of nucleoprotein complexes.  An aliquot of 400ul of chloroform 
was added to the Trizol homogenate and shaken vigorously for 15 seconds.  The tubes were then 
placed on ice for 3 minutes. 
 
Following centrifugation at (12 000 rpm for 15 minutes at 4 C) the sample was separated into 
three phases.  The RNA was located in the upper phase and was clearly separated from the 
interphase and the lower phase, which contained DNA and protein.  If the upper phase was not 
clear, additional chloroform may be added and the centrifugation repeated.  Without disturbing 
the interphase, the upper phase was transferred to a labeled 1.5 ml microfuge tube.  If there was 
disruption of the interphase, centrifugation was repeated.  The protein and DNA were stored at -
80 C for DNA isolation if necessary.  An aliquot of 500 ul cold isopropanol (Sigma; SA; 
Molecular Biology Grade) was added to the supernatant.  The tubes were incubated on ice in the 
cold room (~4 ºC) for 2 hours or overnight. 
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After centrifugation (12 000 rpm for 10 minutes at 4º C) the supernatant was decanted without 
disrupting the pellet, and 1ml of cold 75% ethanol (Merck, BDH, Molecular Biology Grade) was 
added to the pellet.  The tubes were centrifuged (8000 rpm for 5 minutes at 4 ºC).  The wash step 
was repeated.  The microfuge tubes were air dried in the biological safety cabinet for 15 minutes.  
An aliquot of 30 ul DEPC water was added to the pellet and placed on the heating block at 55 ºC 
for 10 minutes.  The RNA was stored at -20 ºC until cDNA synthesis (within 3 days).  The RNA 
was then stored at -80 ºC and the cDNA was stored for up to six months at -20 ºC. 
 
2.7  Analysis of RNA 
 Ribonucleic acid quantity and quality was assessed using the Nanodrop ND-1000 
spectrophotometer (Inqaba, SA).  A volume of 1ul of sample was pipetted onto the testing pedal 
of the instrument and the concentration and purity was measured.  The ratio of absorbance at 260 
and 280 nm (i.e. the A260/A280 ratio) was used to determine the purity of RNA.  The A260/A280 for 
the RNA should be ≥1.8 and the expected concentration of the RNA was greater than or equal to 
200 ng/ul. 
 
2.8  RT-PCR 
RNA was converted to cDNA using the standardized EAC Reverse Transcription protocol 
(Gabert J et al; 2003).  2ul of RNA, 2ul of random hexamer (Promega, USA, 500ug/ml) and 
DEPC treated water was added to give a total volume of 9ul. This reaction was performed using 
the GeneAmp PCR System 9700 (Applied Biosystems, Ver3.12; USA).  It was denatured for 10 
minutes at 70 ºC and then immediately cooled on ice for 5 minutes.   
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The EAC mastermix consisted of the following reaction components: 5 X Expand reverse 
transcriptase buffer (first strand) (Invitrogen, S.A), 5mM MgCl2 (Roche), dNTP (10mM each), 
100mM DTT (Anatech Instruments; SA), 40U/ul RNAse Inhibitor (Anatech Instruments; SA), 
200U/ul Superscript III Reverse Transcriptase (Invitrogen; SA).  A volume of 11ul of EAC 
mastermix was added to the denatured RNA isolates and made up to a total volume of 20ul with 
molecular grade PCR water (Roche; SA).  These samples were quick spun at 12000 rpm and then 
run on the GeneAmp PCR System 9700 (Applied Biosystems, Ver3.12; USA) at 25 
o
C for 10 
minutes, 42 
o
C for 45 minutes, 99 
o
C for 3 minutes and then cooled to 4 
o
C.  The amplified 
cDNAs were spun at 12000 rpm and kept at 4 
o
C until required for the PCR reaction (immediate 




2.9  Optimization of In-house Real-Time PCR assay 
When this study began in 2007, a RT-PCR assay for the detection of PML-RARA isoforms was 
not available in our laboratory. At this time, commercial qPCR kits were also not available. The 
initial objective was therefore to develop a rapid in-house RT-PCR assay on the Light Cylcer 2.0 
(Roche SA) (Appendix 3).  Primers and probes as shown in Table 2.1, published in the journal, 
















Table 2.1:  Primers for RT-PCR analysis of t (15; 17) (q22;q21)  




 Sequence (5_±3_) 
 (size)  
    
PML-A1(F) 1438 (21) CAGTGTACGCCTTCTCCATCA 
PML-A2(F) 969 (18) CTGCTGGAGGCTGTGGAC 
RARA-B(R) 485 (20) GCTTGTAGATGCGGGGTAGA 
PML-C1(F) 1546 (21) TCAAGATGGAGTCTGAGGAGG 
PML-C2(F) 997 (19) AGCGCGACTACGAGGAGAT 
RARA-D(R) 426 (20) CTGCTGCTCTGGGTCTCAAT 
RARA-E3(R)_ 682 (20) GCCCACTTCAAAGCACTTCT 




The HL60 and NB4 cell lines (Sigma; SA) were ordered to use as controls for the reaction.  To 
attempt to make the PCR faster, a single round real time PCR was optimized with the assistance 
of Roche.  The master mix for the in-house PCR consisted of the following in a final volume of 
20ul: 2 ul cDNA; 200uM dNTP; 400nM primers; 2.5 mM. MgCl2; PCR buffer (20 nM Tris HCl, 
50 mM KCl, pH 8.3) and 0.5U Amplitaq Gold.  The run conditions were as follows for 35 cycles: 
94 
0
C for 30s (melting), 65 
0
C for 60s (annealing) and 72 
0
C for 60s (extension).  The same 
primers (Roche; SA) as listed in Table 2.1 were used in different combinations to amplify the 
different breakpoints (PML-A1+RARA-B: bcr1);(PML-A2+RARA-B: bcr2);(PML-A2+RARA-
E3: bcr3).  A primer stock concentration of 100 pmol was supplied.  A working stock of primer 
concentrations from 8 pmol to 20 pmol were tested for the optimal concentration.  Sensitivity 
assays were run on the LC 2.0 with dilutions of the NB4 cell line used as a positive control and 
HL60 as a negative control.   
 
2.10  Quantitative Real-time PCR using the Ipsogen qPCR fusion kit 
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The IPSOGEN qPCR fusion kit assay (Barker Medical; France) was used to obtain the final gene 
transcript ratio in copy numbers and the bcr isoforms (presented in the thesis) used for data 
analysis in this study, due .to lack of sensitivity of the in-house real-time PCR assay. 
 
 
Figure 2.1:  Diagram of probe and primer set from Ipsogen bcr1, bcr2 and bcr3 handbook 
used in the qPCR assay 
Schematic diagram of the PML-RARA FG transcript covered by the EAC qPCR primers and 
probe set.  For type bcr1 (L):  ENF903–ENP942–ENR962. For type bcr2 (V): 
ENF906–ENP942–ENR962.  For type bcr3 (S): ENF905–ENP942–ENR962. 
The number under the primers and probe refers to their nucleotide position in the normal gene 
transcript.  Relative frequency refers to the proportion of each type of FG transcripts among 
PML-RARA variants. 
 
The PML-RARA Ipsogen bcr1, bcr2 and bcr3 (Barker Medical; France) kits were used according 
to manufacturer’s instructions.  The kit contains different mastermix for both target and 
housekeeping genes.  The probes used in the bcr1, bcr2 and bcr3 kits as shown in (Figure 2.1).  
 41 
The principle of the reaction is described in (Figure 2.2).  There are five plasmid DNA target 
(PML-RARA) standards supplied at a dilution of 1 million copies to 10 copies as per (Table 2.2).  
These standards are used to generate the standard curve for quantification of the PML-RARA 
gene.  Due to the particular technological requirements, it was recommended that LC 2.0 
experiments must be performed with the LC Taqman Master (Roche, South Africa).  All reagents 
were thawed and placed on ice.  The qPCR mastermix was prepared according to the number of 
samples being processed as shown in (Table 2.2). 
 
Table 2.2:  Preparation of qPCR mastermix for bcr isoforms 
 
Component 1 rx (ul) 







Freshly prepared LC Taqman 
MM (x5) 
4.0 60 68.0 1x 
Primers and Probe Mix (25x) 0.8 12 13.6 1x 
Nuclease free PCR grade 
water 
10.2 153 173.4 - 
Sample to be added 5.0 5.0 5.0 - 





Figure 2.2:  Reaction principle adapted from Ipsogen handbook:  
cDNA is amplified by PCR using a pair of specific primers and a specific internal double-dye 
probe (FAM™–TAMRA™).  The probe binds to the amplicon during each annealing step of the 
PCR.  When the Taq extends from the primer bound to the amplicon, it displaces the 5' end of the 
probe, which is then degraded by the 5' 3' exonuclease activity of the Taq DNA polymerase.  
Cleavage continues until the remaining probe melts off the amplicon.  This process releases the 
fluorophore and quencher into solution, spatially separating them and leading to an increase in 
fluorescence from the FAM and a decrease in fluorescence from the TAMRA. 
 
In each capillary 15ul of the qPCR mastermix and 5ul of the RT product (cDNA, ~100ng RNA 
equivalent) obtained from the RT-PCR (EAC; 2003) and the dilution standards and negative 
control was added for each experiment.  The reaction was mixed gently by pipetting up and 
down.  The capillaries were placed in the adapters provided with the apparatus and spun down at 
 43 
3000 rpm for 30 seconds.  The capillaries were then loaded into the thermal cycler and run at the 
program specified in (Table 2.3).  It was recommended by the manufacturer to use the Automated 
(F'max) analysis on the LC 2.0 Software 4.0 to obtain reproducible results.  Thermal cycling 
conditions were carried out according to manufacturer recommendations as shown in (Table 2.3).  
 
Table 2.3:  Thermal cycler conditions for LC 2.0 




 Time: 10 minutes 
 Ramp: 20 
Cycling 50 times 
 95
 o
C for 10 seconds; ramp:20 
 60
 o
C for 1 minute; ramp: 20; with acquisition of 
 FAM fluorescence: Single 
Hold 2 45
 o
C for 1 minute;ramp: 20 
 
2.11  Methods applied to the interpretation of qPCR data 
2.11.1  Analysis of Data 
Data was analyzed using the absolute quantification in the LC 2.0 software 4.1.  Using standards 
with a known number of molecules, a standard curve was established to determine the precise 
amount of target present in the test sample.  The Ipsogen standard curves are plasmid-based.  A 
housekeeping gene was run simultaneously as a control for each unknown sample. 
 
For each gene (ABL and PML-RARA), raw Cp values obtained from plasmid standard dilutions are 
plotted according to the log copy number.  A negative control was used in all assays to control for 
amplicon contamination.  A positive control was not run in every assay as the standards were 
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dilutions of known concentrations of the PML-RARA fusion gene.  Also, an ABL housekeeping 
gene was run with every sample to control for the integrity of the RNA.  If the housekeeping gene 
had a value below 1000 copies the RNA was considered to be degraded.  When the positive 
control was run (usually twice a month or when a new kit was opened) it was a known positive 
patient’s sample that was used or RNA extracted from the NB4 cell line lyophilized pellet 
(Sigma, Capital Labs).  The LC 2.0 software has a feature to import previously run standard 
curves to analyze the data only if the standards run in the present assay passes after analysis in 
the absolute quantification of the LC 2.0 software 4.1.  In addition, a PCR assay with efficiency 
less than 1.5 was considered unsuccessful and the assay was repeated.  Also, a Cp value <10 or 
>35 indicated false positivity and amplification in the negative control indicated amplicon 
contamination.  Initially samples were run on a gel to verify the products.   
 














 F1- 10 ABL 10
3
 C1- 1000 
PML-RARA bcr1 10
2
 F2- 100 ABL 10
4
 C2- 10000 
PML-RARA bcr1 10
3
 F3- 1000 ABL 10
5
 C3- 100000 
PML-RARA bcr1 10
5
 F4- 100000 - - 
PML-RARA bcr1 10
6
 F5- 1 000 000 - - 
 
 
2.11.2  Normalized copy number (NCN) 
The ABL standard curve equation was used to transform raw Cp values (obtained with PPC-ABL) 
for the unknown samples into ABL copy numbers (ABLCN).  The PML-RARA standard curve 
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equation was used to transform raw Cp values (obtained with PPF-PML-RARA) for the unknown 
samples, into PML-RARA copy numbers (PML-RARA CN). 





 RARA  - PML
x 100% 
 
The result was reported as a percentage of the target fusion gene and the housekeeping gene.  The 
result was considered invalid and not reported if the housekeeping gene was below a 1000 copies. 
The sensitivity of the assay was 10
-3 
after serial dilutions was run in duplicate with positive 
patient’s sample.  Positive and negative samples were determined by the percentage of the target 
gene divided by the housekeeping gene.  A result of 0% was considered negative and a result 
greater than 0, 1% was considered positive also, a crossing point (CP) of >35 was rejected as a 
false positive and a CP <10 was considered negative. 
 
2.11.3  MRD value 
The minimal residual disease (MRD) value was the ratio between the CG normalized expression 
of the FG in the follow-up (FGCN/ CGCN) FUP and diagnostic samples (FGCN/ CGCN) DX. 







2.12  Verification of PML-RARA qPCR assay 
In the Europe against Cancer Program (EAC) 25 laboratories from 10 countries collaborated to 
establish a standardized protocol for Taqman-based real-time quantitative PCR (qPCR) analysis 
of the main leukemia-associated fusion genes.  Four phases were scheduled: training, 
optimization, sensitivity testing and patient sample testing.  There were three quality control 
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rounds on a large series of coded RNA samples, which enabled the final validation of the primer 
and probe sets for ALL, AML and CML (Gabert J et al, 2003). 
All three breakpoints for the PML-RARA were evaluated.  The only cell line available for testing 
was the NB4 which has a bcr1 PML breakpoint.  For the bcr2 and bcr3 primer/probe sets 
diagnostic patient’s bone marrow RNA was used.  EAC data revealed that no significant 
difference was observed in PML-RARA bcr3 expression when comparing peripheral blood and 
bone marrow on paired samples.  Overall the frequency of false positivity was 6.9% and was 
limited to individual laboratories were the (crossing threshold) Ct value in the false-positive well 
was always more than 30 and most of the time higher than 35.  From the 96 samples tested there 
were no false-negatives for bcr1, 2 or 3 and the assay had a sensitivity of 10
-3
 (Gabert J et al, 
2003). 
 
2.13  Statistical Analysis 
Statistical analysis of data was performed in consultation with a statistician from the department 
of Bioethics and Research, UKZN, Dr Benn Sartorius (PHD) (UKZN).  All tests were performed 
using Strata 13.  Non parametric Fisher’s exact test and Kruskal Wallis test were used to analyze 






























3.1  Results  
3.1.1  Patient cohort 
  
Figure 3.1 shows the breakdown of Acute Leukemia patients attending the Onco-Haem clinic at 
IALCH, KZN, South Africa from January 2007 to December 2009.  A total of 91 acute leukemia 
patients were referred to IALCH from peripheral hospitals in KZN during that period.  The 
patients were classified by clinical hematologists into the different types of leukemia’s using the 
WHO (2016) classification as shown in Chapter 1, Figure 1.2.  The incidence of APL was 25% at 
our hospital.  The frequency of AML in this cohort was 69% (63 out of 91) and out of these, 35% 
(22 out of 63) were identified as APL (by differential morphology screening and flow cytometry).  
The remainder of the AML patients (40 out of 63) were adults with translocations other than the t 
(15; 17) (q22; q12) translocation, or children.  One patient out of the 63 AML patients had a 
variant t (15; 17).  
 
 
Figure 3.1: Diagram representing classification of Acute Leukemia patients visiting the 





63 AML patients 28 patients had other types 
of Acute Leukemia 
40 other AML patients 23 APL patients 
Diagnosed by differential 
morphology screening  
cytometry 
22 PML-RARA 1 PLZF-RARA 
Diagnosed by qPCR 
bcr isoforms Diagnosed by FISH 
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3.2  Optimization of In-house Nested RT-PCR 
 
We attempted to develop an in-house RT-PCR assay, to determine the different bcr isoforms, 
based on the method described by van Dongen J J M et al,1999.  Only three out of seven samples 
(Figure 3.2: lanes 6, 7 and 8) were amplifiable, producing a 1329bp product after the first round 
of PCR. Most of the samples that could not be detected had low concentrations of RNA (below 
4ng/ul as shown in (Appendix 1)).   
        







Figure 3.2:  RT-PCR results from the first step of a nested PCR assay.  Products were run 
on a 2% agarose gel.  Lane 1 (L1) contained a 100bp ladder (Roche, SA).  L2 to L8 had 
patient samples: 183, 189; 191, 197, 199, 202, and 203.respectively.  L6 to L8 showed 
positive PCR products. 
 
After a second round of amplification using internal primers to increase the sensitivity of the 
PCR, three out of seven samples were amplified producing a 381bp product.  However, numerous 
non-specific bands were also seen as shown in Figure 3.3.  This did not improve after the titration 
of the primer and Mg
2+












Figure 3.3:  RT-PCR results from the second round of nested PCR showing amplification of 
the positive products from the first round of PCR.  L2, L8 and L15 were loaded with 










Figure 3.4: Sensitivity of the in-house RT-PCR assay.  Lane 1 shows a 100bp ladder 




).  The 
HL60 negative strain was run in Lane 6 and Lane 7.  
 
The sensitivity of the assay was also assessed using the NB4 cell line as a positive control (Figure 
3.4).  The NB4 cell line could only be detected at the highest concentration of 10
7 
copies.  No 
bands were seen for lower copy numbers.  The HL60 cell line was used as a negative control.   
  








1 2 3 4 5  6 9 10 11 12 13 14   15   16 8 
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PCR products were run on 2% agarose gel.  The product was only visible at the undiluted 
concentration of the NB4 cell line showing that the PCR was not sensitive enough.   
 
3.3  Optimization of In-house Real Time PCR on the LC 2.0 
After numerous attempts at optimizing the in-house PCR assay, a new assay was developed on 
the Light Cycler 2.0 as a real-time PCR assay, as this technique was known for improved 
sensitivity and the generation of rapid results.  The Fast Start Sybr Green kit (Roche; SA) was 





Figure 3.5:  (A) LC 2.0 results showing optimization of annealing temperature.  (B) LC 2.0 
results showing MgCl2 titration of a positive patient’s sample.  (C) LC 2.0 results showing 
primer titration of a positive patient’s sample.  (D) Serial dilutions of NB4 and HL60 cell 








C.  Figure 3.5(A) shows the result 
of a positive sample that amplified at the correct melting temperature (Tm) of 92 
o
C when an 
annealing temperature of 65
 o
C (green) was used.  The MgCl2 was titrated from 3.0 mM to 1.5 
mM.  A concentration of 2.5 mM (shown in blue in Figure 3.5(B) was taken as optimum.  Results 
for the primer titration are shown in Figure 3.5(C).  The primers were titrated from 20 pmol/ul to 
8 pmol/ul at intervals of 2 pmol/ul.  The optimal primer concentration was found to be 8 pmol/ul 
(shown in black).  Serial dilutions with the NB4 and HL60 cell line was unsuccessful as the PCR 




3.4  Ipsogen qPCR Results for PML-RARA bcr Isoforms of the Patients samples 
Due to the in-house assays not being sensitive enough, a qPCR kit from Ipsogen (Barker 
Medical; France) was used to identify the PML-RARA bcr isoforms in APL patients with the t 
(15;17).  In addition, the qPCR kit allowed for the quantitation of the transcripts which was 
helpful for the monitoring of MRD during patient follow-up after treatment.  Serial dilutions 
(from 100 000 copies to 10 copies) of a plasmid standard of the PML-RARA bcr1 isoform was 
used to establish the standard curve for the target gene as shown in (Figure 3.6).  Similarly, 
plasmid standards of the ABL gene (Barker Medical; France) with serial dilutions of a 100 000 
copies to 10 copies were used to establish the standard curve for the housekeeping gene as shown 













Figure 3.6:  Results from the raw data of a bcr1 qPCR on the LC 2.0 which is tabulated in 
(Table 3.1).  There are data sheets available for all patients in (Table 3.1).  The efficiency of 
the PCR was 1.9.  The positive, negative controls and the bcr1 standards all passed.  The 
housekeeping gene for all the samples run was greater than 1000 copies. 
 
One patient from the AML cohort presented with morphological and clinical characteristics of 
APL but did not have the PML-RARA transcript by qPCR.  Subsequently, the variant PML-RARA 
transcript was detected by FISH in this patient, and was excluded from further analysis. 
 
In the study 68% (15/22) peripheral bloods and 32% (7/22) bone marrow aspirates were received 





Table 3.1:  Demographic positive qPCR results of APL patients at diagnosis with bcr1 
isoform (pink) and bcr3 isoform (blue) and bcr2 isoform (white) 
PATIENT 
ID 




GENE - ABL 
RATIO % 
1 385 BONE MARROW 356000 173000 2.06 205.8 
2 443 BLOOD 3030 7450 0.41 40.67 
3 429 BLOOD 19100 12200 1.57 156.6 
4 490 BLOOD 250000 94500 2.65 264.6 
5 438 BLOOD 2330 10400 0.22 22.4 
6 1064 BONE MARROW 101000 83900 1.2 120.38 
7 270 BLOOD 106000 73400 1.44 144.4 
8 674 BLOOD 29400 4960 5.93 592.7 
9 1069 BLOOD 62300 83900 0.74 74.25 
10 606 BLOOD 95500 116000 0.82 82.33 
11 366 BONE MARROW 3390 4480 0.76 75.67 
2 1859 BLOOD 24800 390000 0.06 6.36 
13 421 BONE MARROW 6300 17000 0.37 37.06 
14 1996 BLOOD 11500 5970 1.93 192.63 
15 1664 BLOOD 73300 60300 1.2 121.56 
16 1772 BLOOD 7030 27400 0.3 25.66 
17 319 BONE MARROW 1470 73100 0.02 2.01 
18 306 BONE MARROW 21200 39500 0.54 53.67 
19 581 BLOOD 24300 3340 7.28 727.5 
20 1529 BLOOD 106000 132000 0.8 80.3 
21 374 BONE MARROW 10700 63100 0.17 16.96 
22 2065 BLOOD 739 4070 0.18 18.16 
  
All the housekeeping genes were over 1000 copies which showed good quality of the sample (a 






Figure 3.7:  Bar graph showing qPCR results of APL patients at diagnosis from data in (Table 
3.1)  
 
The frequency of PML-RARA (L) bcr1 isoform in 22 positive patients was (1/22) 4,5% in Whites; 
(8/22) 36,4% in Indians and (5/22) 7% in Africans.  PML-RARA (V) bcr2 isoform was (1/22) 
4,5% and PML-RARA (S) bcr3 isoform was (4/22) 18,2% in Indians and (3/22) 13;6% in 
Africans (as shown in Figure 3.7).   The Indian population showed predominance in the bcr1 and 
bcr3 isoforms while the bcr2 had only one African positive patient. 
 
3.5   Clinical and Hematological Parameters 
The 22 newly diagnosed adult APL patients were followed up for two years.  A summary of their 
patient characteristics are given in Table 3.2.  Clinical features and hematological parameters 
such as Hb, WCC, and platelet count (Table 3.5) were used to stratify patients into different 
prognostic groups (as described in section 2.1).   
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Table 3.2:  Summary of patient’s hematological parameters 
No. of patients 22 
M:F ratio 1:1 
Median Age 30 years ( Range 21-68 years) 
Median Hb  7.5g/dl (Range 4.5-11.4 g/dl) 
Median Aptt 23.4 seconds (Range 25-40 seconds) 
Median D-dimer 4.04 ug/ml (Range 2.5-16.0 ug/ml) 
(Normal value <0.25 ug/ml) 
Median Fibrinogen 3.0 g/l  (Range 1.0-6.9 ug/ml) 
(|Normal value 1.5-4.5 g/l) 
Median INR 1.15 (Normal value <1.2) 
Median Platelet Count 45 x10
9
/l (Range 4.6-430 x10
9
/l)  
Normal value (171-454 x10
9
/l) 
Median WCC 5.0 x10
9
/l (Range 0.83-29 x10
9
/l) 
Normal value (3.90-12.6 x10
9
/l) 
Low risk group 1 patient 
Intermediate risk group 15 patients 
High risk group 6 patients 
 
As shown in Table 3.2, there was an equal male to female ratio in the 22 patients.  The median 
age group for our cohort was 30 years of age.  Majority of the patients had a low platelet count 
with a median of 45 x10
9
/l and fell into the intermediate risk group.  Six patients were high risk 
according to the risk stratification explained in section 2.1.  The median Hb was 8.0g/dl, the 
median white cell count was 5.0 x10
9















WCC PLTS WCC PLTS 
1 2/27/2007 29 4.55 08/02/2007 7.32 8.6 
2 5/2/2007 13.7 11 05/03/2007 demised demised 
3 4/17/2007 2.51 9.2 10/09/2007 3.03 176 
4 7/5/2007 3.89 54 07/08/2007 4.85 109 




6 6/19/2008 1.44 37 07/23/2008 2.11 213 
7 9/19/2006 8.31 36 10/02/2006 4.04 46 
8 11/22/2007 7.7 177 01/30/2008 7.36 190 
9 6/23/2008 0.83 92 07/14/2008 6.30 134 
10 9/19/2007 0.84 35 12/18/2007 6.30 134 
11 1/23/2007 2.72 266 03/14/2007 8.96 273 
12 6/19/2009 20.7 34 07/02/2009 10.39 15 
13 4/10/2007 6.7 285 05/28/2007 3.99 178 
14 8/26/2009 3.22 109 09/01/2010 3.49 220 
15 3/26/2009 1.31 53 04/27/2009 3.49 192 
16 05/13/2009 1.54 17 06/19/2009 6.75 242 
17 11/16/2006 13.84 33 01/02/2007 7.34 283 
18 02/11/2006 7.77 21 03/11/2006 3.13 46 
19 8/28/2007 9.33 296 09/25/2007 9.10 332 
20 2/5/2009 0.9 31 03/02/2009 10.05 315 
21 2/7/2007 3.21 315 03/08/2007 5.77 241 
22 9/28/2009 6.04 430 10/27/2009 4.69 375 
  
 
Most of the patients in all isoforms presented with pancytopenia and thrombocytopenia as shown 
in Table 3.3.  After treatment with ATRA all patients (Table 3.3) showed corrected WCC and 










Table 3.4:  Summary of statistical analysis  
Statistic Analysed p-value 
bcr isoform compared to the 
patients that died 
1.000  
Patients died by HIV status 1.000  
Bcr isoform compared by race 0.870  
bcr  isoform compared by gender 0.814  
bcr isoform compared by age 
Significant 
difference by age 
0.03 





There was no significant association of the bcr isoforms with statistical data analyzed such as, 
HIV-1 infection, race, gender and WCC and platelets (Table 3.4) by the Fisher’s exact test.  
However, there was a significant association between the patient’s age and bcr isoforms with a 
probability of 0.03 (Table 3.4) based on the Kruskal Wallis test.  Bcr1 and bcr2 isoforms were 
significantly associated with younger patients (20-30 years), while the bcr3 isoform (was 










3.6  Bcr Isoforms and treatment outcome: 
Knowledge of bcr isoforms by qPCR provides independent prognostic information for treatment 
stratification (Table 3.5 and Table 3.6).  In this study, qPCR was used to monitor patients for 
MRD (i.e. relapse or remission).  The patients were listed in Table 3.5 and 3.6 in order of their 
follow-up dates to the Onco-Haem Clinic at IALCH.  The majority of the patients completed 
their induction and maintenance as per treatment guidelines stipulated in section 2.4.1.  A few 
(n=5) of the patients had to have alternate individualized therapy depending on the adverse 
effects reported.  As part of patient management, APL patients are closely monitored by clinical 
hematologists to prevent relapse and minimize adverse side effects of the chemotherapy by 
individualizing treatment for each patient as stipulated in Tables 3.5 and 3.6. 
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Table 3.5:  APL Patients with bcr1 isoform – presenting clinical features and treatment regimen 








INDUCTION CONSOLIDATION MAINTENANCE STATUS COMMENT 
7 Neg 8.2 26 Intermediate 6.26 completed completed completed lost to f/up HIV later 
13 Neg 11.4 15 Intermediate 3.77 completed completed completed remission  









10 Pos 8.3 29 Intermediate 0.69 Daunorubicin 





4 Neg 4.5 7 Intermediate 4.97 
Daunorubicin 
+ATRA 
Idarubicin x3 completed remission-well 
continues to 
follow-up 
3 Neg 8.5 38 Intermediate 3.08 
Daunorubicin 
+ATRA 





12 Neg 8 34 poor 22.48 
Daunorubicin 
+ATRA 





5 Pos 8.8 36 Intermediate 9.56 
Daunorubicin 
+ATRA 
Idarubicin x3 and ATRA completed remission-well 
continues to 
follow-up 
9 Neg 9.4 92 good 0.83 
Daunorubicin 
+ATRA 





2 Neg 6.3 11 Intermediate 13.7 
died within 24 
hours of 
admission 
N/A N/A demised N/A 
6 Neg 7.4 14 Intermediate 1.4 
Daunorubicin 
+ATRA 
defaulted follow up N/A demised N/A 
8 Neg 7.7 16 Intermediate 1.38 
Daunorubicin 
+ATRA 
idarubicin x3, Mitoxantrone 




11 Neg 8.5 20 Intermediate 3.4 
Daunorubicin 
+ATRA 
idarubicin x3, Mitoxantrone 




14 Neg 9.1 21 poor 0.76 
Daunorubicin 
+ATRA 
Etoposide and Cytarabine not in remission lost to f/up  
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Table 3.6.  APL Patients with bcr 3 isoform- presenting clinical features and treatment regimen 
 
Pt ID HIV CD4 Hb Plt WCC PROGNOSIS INDUCTION CONSOLIDATION MAINTENANCE STATUS COMMENT 






















































































































4.1  DISCUSSION 
 
Lack of population–based registries in developing countries has made it difficult to determine the 
real incidence of APL in countries like Africa, Latin America and India.  This is due to the lack 
of well-structured networks and the accrual of large number of patients.  The number of samples 
is limited as APL is a subordinate, sub-class of AML which is further classified into the different 
bcr isoforms.  In 2004, the International American Society of Hematology (ASH) proposed the 
creation of a group, the International Consortium of APL (IC-APL) for collaboration of data in 
developing countries (Niemeyer C et al, 2006).  
 
Inkosi Albert Luthuli Central Hospital is the only referral center for all acute leukemia patients in 
KZN, as only chronic leukemia patients are seen at other peripheral hospitals.  It has been 
reported in a  study by (Herbst M C, 2015) that approximately 25% of acute leukemia patients 
are AML and from this 10% are diagnosed with APL in South Africa  The prevalence of APL 
was found to be higher, 36,5% of AML’s compared to other South African and South American 
studies.  Rego and coworkers, (2013) have reported that APL accounts for 28,2% of all AML 
cases in centers in Brazil.  This information is ratified by other studies, Mexico (20%), Peru 
(22%) and Venezuela (27,8%) (Rego E M et al, 2013).  However, this is much higher than 
reported cases found in Eastern countries.  In a study in India it was found that APL accounts for 
10% of AML cases in adults (Bajpai J et al, 2011; Sazwal S et al, 2009 and Dutta et al, 2000). 
 
Molecular techniques such as qPCR have made it possible to diagnose and quantify the leukemia 
burden of APL patients according to their PML-RARA bcr isoforms.  This is important for MRD 
monitoring which is pivotal for individualized treatment regimens and molecular targeted 
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therapy such as ATRA which tends to induce terminal differentiation of the PML-RARA 
transcript. 
 
In this study bcr1 was found to be the predominant PML-RARA isoform by qPCR which is in 
keeping with studies published by western countries (Douer D et al, 2003; Lo Coco F et al, 2003 
and Grimwade D et al, 1998).  This was also the main isoform found in our South African 
cohort, who was mainly of Indian and African ethnic group due to the population demographics 
found in KZN. 
 
It has been reported that patients with the bcr3 isoform generally have a poor prognosis  (Slack J 
L et al, 2000; Chatterjee T et al, 2014). The bcr3 is associated with a shorter remission duration 
and overall survival compared to the other isoforms (Gonzalez M et al, 2001; Sanz M A et al, 
2000).  In the study of Chatterjee T et al, (2014) five patients died during the induction phase, 
three of which had the bcr3 isoform.  Due to the large Indian population in our cohort (12 out of 
22 patients) we compared our findings to the studies in India. We did not find an over-expression 
of the bcr3 isoform in our Indian patients as compared to studies from India (Sazwal S et al, 
2009 and Dutta et al, 2000). 
 
Although KZN, South Africa has a high African and Indian population, our study is comparable 
to findings from other studies in the West where the predominant population is white.  Therefore, 
we can conclude that the ethnic group of the patient does not influence the bcr isoform or the 




There were no reports of the unusual features of gum hypertrophy in our patients which was seen 
in the other studies in India (Chatterjee T et al, 2014).  This study did not show an association 
between the bcr3 isoform and high WCC and the PML-RARA variant bcr2 isoform and high 
WCC at presentation like the other studies (Sazwal S et al, 2009).  The patients are significantly 
younger in our cohort as previous studies have reported a median age of 45 (Chatterjee T et al, 
2014).  This could have attributed to the overall wellness of our patient cohort and the majority 
of patients responding positively to treatment. 
  
Only one patient was diagnosed with the variant bcr isoform, also called bcr2. This is usually 
associated with a poor prognosis; however, after standard treatment of induction with ATRA and 
Daunorubicin and then consolidation twice with Idarubicin and ATRA, He was reported to be 
well after 23 months of treatment. 
 
One patient diagnosed with the variant PLZF-RARA rearrangement using FISH was excluded 
from the qPCR isoform analysis.  The PLZF-RARA rearrangement has been reported to have 
atypical APL morphology, such as regular nuclei and hypo or microgranular cells, abundant 
cytoplasm, more condensed chromatin pattern in blasts, absence of auer rods and increased 
number of Pelgeroid neutrophils (Sainty D et al, 2000).  However, our patient did not show this 
atypical morphology, as the slides presented with normal granules and auer rods.  The APL 
variant form although rare, offers a challenge to its early recognition which can be achieved 
through careful morphological analysis, clinical presentation, cytogenetic tests and FISH (Sandra 
S R, 2011).  From a therapy point of view, usually t (11; 17) strongly blocks differentiation, so 
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the PLZF-RARA variant is characterized by poor response to retinoids as a single agent and also 
to arsenic trioxide (Mistry A R, 2003).  Conversely, a number of studies have suggested that this 
subset of APL is not completely resistant to differentiation and therefore would respond to 
ATRA.  In this study, the single patient with the PLZF variant was ATRA responsive achieved a 
short remission, after which the patient relapsed and thereafter demised (Lo Coco F et al, 1998; 
Bajpai J et al, 2011).   
 
One patient was positive for all three isoforms bcr1, 2 and 3.   However, this was not confirmed 
by sequencing. There are no other reported cases of patients with all three bcr isoforms 
worldwide.  A larger cohort of samples needs to be investigated to determine if this is common 
in KZN.  Despite an initial intracranial bleed this patient responded to individualized therapy.  
 
Abnormal results were observed for all hematological parameters for the majority of patients.  
The most significant characteristic observed in our cohort of patients was a median platelet count 
of 45.  This low platelet count can be attributed to the DIC observed in majority of these patients 
which is consistent with clinical features of APL.  In previous studies of cytotoxic chemotherapy, 
early deaths during induction in patients with APL occurred primarily as a consequence of 
intracranial hemorrhage (Breccia M et al, 2010; Park J H et al, 2011; Bai H E et al, 2013.   
 
There was no significant correlation between the PML-RARA isoforms and hematological 
parameters with response to treatment (p=1.000).  While this finding is similar to previous 
studies (Grimwade D et al, 1996; van Dongen JJM et al, 1999; Gabert J et al, 2003), a limitation 
of this study is that the sample size may not have the power to detect such a relationship. 
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Minimal residual disease monitoring with qPCR for the detection of the PML-RARA transcript is 
known to be crucial for APL patients as it identifies the risk of relapse and predicts long–term 
remission (Mandelli F et al, 1997).  The overall survival of our patients was 90.9% and it was 
found that 72.7% (16 out of 22 patients) had a disease free survival.  At present three patients 
have demised and three have been lost to follow up but were well and in remission up until 2011.  
Presently sixteen patients remain well and in remission (Unpublished communication, 
S.Parsanath). 
 
While long-term prognosis of APL in the setting of HIV-1 is currently unknown, the two APL 
patients with HIV in our study (one bcr1 and one bcr3) responded well to ATRA and 
chemotherapy while on anti-retroviral therapy and remain well and in remission, suggesting that 
APL patients with HIV do not necessarily have a poor survival rate.  This compares well with 
complete remission and long term survival rates of 70-95% in uncomplicated APL.  Other 
studies have also found that remission can be successfully induced and maintained with standard 
therapy and little interference of HAART (Sutton L et al, 2001; Boban A et al, 2009).  Although 
CD4
+
 cell counts were reduced during chemotherapy, this increased once treatment was 
completed, and the patients did not suffer any AIDS-associated complications (Kudva G C et al, 







4.2  Conclusion 
A higher prevalence (36,5%) of APL was found in our cohort of AML patients during the study 
period as compared to other studies.  The bcr1 (63,6%) was found to be the predominant isoform 
in our population which is in accordance with reports from western countries (Grimwade D et al, 
1996; van Dongen JJM et al, 1999).  Our study confirmed other published data, (Vahadat L et al, 
1994; Sazwal S et al, 2009; Chatterjee T et al, 2014) which have reported the bcr3 isoform to 
have poor prognosis and overall survival in APL patients. 
 
Although it is a small group of patients, we can conclude from the statistical analysis of our 
patients that the good response to treatment across all isoforms maybe attributed to the majority 
of young adults (below 35 years) in our cohort who may tolerate the aggressive treatment better 
than their older counterparts. There are no previous reports on the significance of age in APL 
patients and the treatment outcomes; therefore further studies on this finding are needed. 
  
There was no significant correlation between different hematological parameters and response to 
treatment.  We have found no difference in prognosis and treatment outcomes in our HIV-
infected and non-infected APL patients.  The PML-RARA bcr subtype also had no effect on 
achieving remission earlier in HIV infected APL patients in our study.  The HIV positive patients 
responded well to treatment with no adverse effects.  Due to the limited number of HIV positive 
APL patients which was also found in other studies (Sutton L et al, 2001) we could not establish 
a conclusive result on the effect of the bcr isoform on treatment response in HIV patients. 
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Patients that remain without a detectable level of PML-RARA transcripts remain well and in 
remission for many years while patients that had detectable levels of PML-RARA transcripts had 
poor treatment outcomes.  Quantitative Real Time PCR monitoring of MRD patients is a useful 
diagnostic tool to monitor APL patients throughout their treatment for hematological and 
molecular relapse.  
 
4.3 Future Work 
 Prospective studies, on a larger cohort of patients are needed to confirm unique and novel 
findings in the molecular pathogenesis of APL patients.  A correlation between other diagnostic 
methods such as immunophenotyping, FISH and qPCR at diagnosis and during MRD will be 
interesting to investigate. For qPCR to be used as an effective diagnostic tool for the detection of 
PML- RARA transcripts, standardization of the housekeeping gene with regards to the expression 
level will be required so that it is possible to monitor the low PML-RARA copy number patients 
as in the Chronic Myeloid Leukemia patients.  Further studies with a larger cohort are required to 
determine if the FLT3 is predominant in the bcr3 isoform and if it contributes to a poor prognosis 
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Appendix 6.2:  Raw Data for Statistical Analysis Results 
No significant difference in died outcome by PCR result using the non-parametric Fishers exact test: 
 
. tab pcrresultcleaned died, row exact 
 
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
+----------------+ 
 
PCR RESULT |         died 
   CLEANED |         0          1 |     Total 
-----------+----------------------+---------- 
      BCR1 |        12          2 |        14  
           |     85.71      14.29 |    100.00  
-----------+----------------------+---------- 
      BCR2 |         1          0 |         1  
           |    100.00       0.00 |    100.00  
-----------+----------------------+---------- 
      BCR3 |         6          1 |         7  
           |     85.71      14.29 |    100.00  
-----------+----------------------+---------- 
     Total |        19          3 |        22  
           |     86.36      13.64 |    100.00  
 
           Fisher's exact =                 1.000 
 
No significant difference in died outcome by HIV status using the non-parametric Fishers exact test: 
 
. tab HIV died, exact row 
 
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
+----------------+ 
 
           |         died 
       HIV |         0          1 |     Total 
-----------+----------------------+---------- 
         0 |        17          3 |        20  
           |     85.00      15.00 |    100.00  
-----------+----------------------+---------- 
         1 |         2          0 |         2  
           |    100.00       0.00 |    100.00  
-----------+----------------------+---------- 
     Total |        19          3 |        22  
           |     86.36      13.64 |    100.00  
 
           Fisher's exact =                 1.000 
   1-sided Fisher's exact =                 0.740 
 
No significant difference in BCR by race using the non-parametric Fishers exact test: 
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. tab RACE pcrresultcleaned , row exact 
 
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
+----------------+ 
 
           |        PCR RESULT CLEANED 
      RACE |      BCR1       BCR2       BCR3 |     Total 
-----------+---------------------------------+---------- 
     ASIAN |         8          0          4 |        12  
           |     66.67       0.00      33.33 |    100.00  
-----------+---------------------------------+---------- 
     BLACK |         5          1          3 |         9  
           |     55.56      11.11      33.33 |    100.00  
-----------+---------------------------------+---------- 
     WHITE |         1          0          0 |         1  
           |    100.00       0.00       0.00 |    100.00  
-----------+---------------------------------+---------- 
     Total |        14          1          7 |        22  
           |     63.64       4.55      31.82 |    100.00  
 
           Fisher's exact =                 0.870 
 
 
No significant difference in BCR by gender using the non-parametric Fishers exact test: 
 
. tab GENDER pcrresultcleaned , row exact 
 
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
+----------------+ 
 
           |        PCR RESULT CLEANED 
    GENDER |      BCR1       BCR2       BCR3 |     Total 
-----------+---------------------------------+---------- 
         F |         6          0          4 |        10  
           |     60.00       0.00      40.00 |    100.00  
-----------+---------------------------------+---------- 
         M |         8          1          3 |        12  
           |     66.67       8.33      25.00 |    100.00  
-----------+---------------------------------+---------- 
     Total |        14          1          7 |        22  
           |     63.64       4.55      31.82 |    100.00  
 
           Fisher's exact =                 0.814 
 
Additional summary of continuous variables to include median and interquartile range 
(p25-p75): 
 
. tabstat AGE WBC PLTS, stats(n mean sd median p25 p75 min max) col(stats) 
 
    variable |         N      mean        sd       p50       p25       p75       
min       max 
-------------+------------------------------------------------------------------------
-------- 
         AGE |        22  33.77273  12.50498        31        24        43        
21        68 
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         WBC |        22      6.93   7.07173     4.965      1.54      8.31       
.83        29 
        PLTS |        22  117.3977  127.6404        45        31       237      




. tabstat AGE WBC PLTS, stats(n mean sd median p25 p75 min max) col(stats) by( 
pcrresultcleaned) long 
 
pcrresultcleaned     variable |         N      mean        sd       p50       
p25       p75       min       max 
------------------------------+-------------------------------------------------------
------------------------- 
BCR1                      AGE |        14  28.78571  7.297824      27.5        
22        34        21        43 
                          WBC |        14  7.751429  8.203698      5.06      2.72      
8.31       .83        29 
                         PLTS |        14  99.05357  100.2496      45.5        
34       177      4.55       285 
------------------------------+-------------------------------------------------------
------------------------- 
BCR2                      AGE |         1        25         .        25        
25        25        25        25 
                          WBC |         1      6.04         .      6.04      6.04      
6.04      6.04      6.04 
                         PLTS |         1       430         .       430       
430       430       430       430 
------------------------------+-------------------------------------------------------
------------------------- 
BCR3                      AGE |         7        45  14.62874        44        
30        55        25        68 
                          WBC |         7  5.414286  4.982766      3.21      1.31      
9.33        .9     13.84 
                         PLTS |         7  109.4286   134.541        33        
21       296        17       315 
------------------------------+-------------------------------------------------------
------------------------- 
Total                     AGE |        22  33.77273  12.50498        31        
24        43        21        68 
                          WBC |        22      6.93   7.07173     4.965      1.54      
8.31       .83        29 
                         PLTS |        22  117.3977  127.6404        45        





Significant difference in age by BCR based on Kruskal Wallis test (non-parametric): 
 
. kwallis AGE, by( pcrresultcleaned) 
 
Kruskal-Wallis equality-of-populations rank test 
 
  +---------------------------+ 
  | pcrres~d | Obs | Rank Sum | 
  |----------+-----+----------| 
  |     BCR1 |  14 |   127.00 | 
  |     BCR2 |   1 |     8.00 | 
  |     BCR3 |   7 |   118.00 | 
  +---------------------------+ 
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chi-squared =     7.013 with 2 d.f. 
probability =     0.0300 
 
chi-squared with ties =     7.057 with 2 d.f. 
probability =     0.0294 
 
No significant difference in WCC/PLT  by BCR based on Kruskal Wallis test (non-
parametric): 
 
. kwallis WBC , by( pcrresultcleaned) 
 
Kruskal-Wallis equality-of-populations rank test 
 
  +---------------------------+ 
  | pcrres~d | Obs | Rank Sum | 
  |----------+-----+----------| 
  |     BCR1 |  14 |   166.00 | 
  |     BCR2 |   1 |    12.00 | 
  |     BCR3 |   7 |    75.00 | 
  +---------------------------+ 
 
chi-squared =     0.151 with 2 d.f. 
probability =     0.9274 
 
chi-squared with ties =     0.151 with 2 d.f. 
probability =     0.9274 
 
. kwallis PLTS , by ( pcrresultcleaned) 
 
Kruskal-Wallis equality-of-populations rank test 
 
  +---------------------------+ 
  | pcrres~d | Obs | Rank Sum | 
  |----------+-----+----------| 
  |     BCR1 |  14 |   156.00 | 
  |     BCR2 |   1 |    22.00 | 
  |     BCR3 |   7 |    75.00 | 
  +---------------------------+  
 
chi-squared =     2.759 with 2 d.f. 
probability =     0.2516 
 
chi-squared with ties =     2.759 with 2 d.f. 




Appendix 6.3  Raw data for graph in Figure 3.7 








bcr1 (14) 22.7 36.4 4.5 
bcr2 (1) 4.5 0 0 
bcr3 (7) 13.6 18.2 0 
        
 
 99 
Appendix 6.4  List of reagents and consumables 
Reagent/Consumable Catalogue no. Supplier 
Promex 18G needles NHN-18-1.5 Scientific Group 
 
 
Trizma Base 93352 Capital Labs 
Promex syringes LPFMSYR-010-LYS Scientific Group 
PCR nucleotide mix C1141 Anatech 
Trizol reagent ISS96018 Lifetech 
RNAse ZAP R2020 Capital Labs 
Propanol MB grade 19516 Monitoring and Control 
Ethanol MB grade 437433T Monitoring and Control 
Chloroform-UNIVAC 1.0244 Merck 
EL Buffer 1014614 Whitehead Scientific 
Superscript III 1880-044 Whitehead Scientific 
Random Hexamers C1181 Anatech 
RNAsin+RNAse inhibitor N2611 Anatech 
Trisure Bio 38032 Celtic Diagnostics 
LC Capillaries 119093390001 Roche 
LC Taqman Master 04735536001 Roche 
PPF BCR1 1071785 Whitehead Scientific 
PPC BCR1 1071652 Whitehead Scientific 
PPF BCR2 1071801 Whitehead Scientific 
PPC BCR2 1071652 Whitehead Scientific 
PPF BCR3 1071802 Whitehead Scientific 
PPC BCR3 1071652 Whitehead Scientific 
Gel Red 41003 Anatech 
Metaphor Agarose  50180 Whitehead Scientific 
Trizma base 93352 Capital ab 
EDTA E4884 Capital lab 










Boric acid B6768 Capital lab 
 
 
 
 
